PharmiWeb.com - Global Pharma News & Resources

Biotech - Press Releases

Date Title Company
11-Feb-2025 JuliaHub Doubles Investment in Advanced Pharmaceutical Modeling Platform JuliaHub
11-Feb-2025 CAR T-Cell Therapy Market Size & Trends | 2025–2035 Vantage Market Research
11-Feb-2025 Pioneer and Novo Nordisk crown Melio Bio winner of 2025 Golden Ticket Programme Pioneer Group
11-Feb-2025 Glox Therapeutics Strengthens Team Appointing Dr Michael Murray as Chair and Dr Nel Moore as Scientific Advisory Board Member Glox Therapeutics
07-Feb-2025 U.S. FDA Grants Orphan Drug Designation to Ariceum Therapeutics’ Proprietary Radiopharmaceutical Cancer Therapy Ariceum Therapeutics
05-Feb-2025 Aqilion Resumes Development of its TAK1-Program Aqilion
04-Feb-2025 ProBioGen Launches New Website to Enhance User Experience and Streamline Access to Expanded Portfolio ProBioGen
04-Feb-2025 Akribion Therapeutics exits from stealth with €8m seed financing to pioneer RNA-guided, programmable cell depletion Akribion Therapeutics
03-Feb-2025 BiocSol secures additional €4.4M to develop its sustainable crop protection solutions Andrew Lloyd Associates
03-Feb-2025 MODERNA WAS THE LARGEST INDUSTRY SPONSOR OF CLINICAL TRIALS IN THE UK IN 2023/24 AS CONSTRUCTION ON MODERNA INNOVATION AND TECHNOLOGY CENTRE IN OXFORDSHIRE NEARS COMPLETION MODERNA
31-Jan-2025 Amicus Therapeutics launches Amicus Ignite, a proactive community funding programme for initiatives that support people living with Pompe disease Amicus Therapeutics
30-Jan-2025 Orion and Invenra announce discovery service and commercial license agreement to develop innovative bispecific antibody cancer therapeutics Orion
30-Jan-2025 Lhasa Limited acquires Molecular Networks and Altamira, leaders in chemoinformatics Lhasa Limited
29-Jan-2025 Dry AMD: SeaBeLife achieves highly promising preclinical efficacy results for SBL03, without injections into eye Andrew Lloyd Associates
28-Jan-2025 VORTEX BIOTECH HOLDINGS ANNOUNCES HIGH PROFILE APPOINTMENT Vortex Biotech Holdings
28-Jan-2025 AB2 Bio signs U.S. option and licensing agreement with Nippon Shinyaku for Tadekinig alfa for an ultra-rare autoimmune disease AB2 Bio
28-Jan-2025 Oncopeptides’ Pepaxti formally approved for full reimbursement in Italy Oncopeptides
28-Jan-2025 Novadip reports 12-month results from phase 1b/2a trial of NVD003 to treat rare pediatric disease Congenital Pseudarthrosis of the Tibia Andrew Lloyd Associates
28-Jan-2025 Unlocking Protein Potential: EvoSelect® and Directed Evolution Isomerase
28-Jan-2025 Isomerase and BugBiome Partner to Advance Sustainable Crop Protection via Targeted Novel Bioinsecticides Isomerase